NEXTCURE INC. DL-,001

NextCure is completing an all-stock deal with Avere Therapeutics and a concurrent private placement totaling $320 million, led by Fairmount and Hansoh. The closing, expected in the second half of 2026, will see the combined company renamed Avere Therapeutics and listed on NASDAQ under the ticker AVRX; NextCure shareholders are expected to hold about 1.21% of the combined company prior to the merger. The financing includes $251 million of convertible notes and a license agreement for Avere’s lead program AVR-001 with upfront and milestone payments of up to $2.18 billion; NextCure shareholders will also receive a contingent value right for possible future monetization proceeds. » More on de.investing.com

NextCure and Simcere Zaiming will present data from the phase‑1 study of the antibody‑drug conjugate SIM0505 at the ASCO annual meeting on June 1. SIM0505 targets cadherin‑6 and carries a topoisomerase‑1 inhibitor payload. It is being studied in advanced solid tumors with particular focus on platinum‑resistant ovarian cancer; the poster presentation will be given by Xiaohua Wu. NextCure holds global rights outside China, Hong Kong, Macau and Taiwan; the company is reported to have a market capitalization of USD 42.4 million and more cash than debt. » More on de.investing.com

NextCure announces data from the dose‑escalation study of SIM0505 for the second quarter of 2026 and at the same time expands the LNCB74 program into higher dose cohorts with priority for tumors with high B7‑H4 expression. Proof‑of‑concept results for LNCB74 are now delayed into the second half of 2026. As of December 31, 2025, the company reported about USD 41.8 million in cash, expected to fund operations into the first half of 2027; NextCure most recently reported negative free cash flow, and three analysts have raised their estimates. » More on de.investing.com